National Institute on Drug Abuse; Notice of Closed Meetings, 64803-64804 [2022-23271]
Download as PDF
<![CDATA[
Federal Register / Vol. 87, No. 206 / Wednesday, October 26, 2022 / Notices
consumer rates of interest on the date
that the Department of Health and
Human Services becomes entitled to
recovery. The rate cannot be lower than
the Department of Treasury’s current
value of funds rate or the applicable rate
determined from the ‘‘Schedule of
Certified Interest Rates with Range of
Maturities’’ unless the Secretary waives
interest in whole or part, or a different
rate is prescribed by statute, contract, or
repayment agreement. The Secretary of
the Treasury may revise this rate
quarterly. The Department of Health and
Human Services publishes this rate in
the Federal Register.
The current rate of 101⁄8%, as fixed by
the Secretary of the Treasury, is certified
for the quarter ended September 30,
2022. This rate is based on the Interest
Rates for Specific Legislation, ‘‘National
Health Services Corps Scholarship
Program (42 U.S.C. 254o(b)(1)(A))’’ and
‘‘National Research Service Award
Program (42 U.S.C. 288(c)(4)(B)).’’ This
interest rate will be applied to overdue
debt until the Department of Health and
Human Services publishes a revision.
David C. Horn,
Director, Office of Financial Policy and
Reporting.
[FR Doc. 2022–23308 Filed 10–25–22; 8:45 am]
BILLING CODE 4150–04–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meeting
lotter on DSK11XQN23PROD with NOTICES1
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Topics in
Motor Function.
Date: November 8, 2022.
Time: 9:00 a.m. to 12:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
VerDate Sep<11>2014
17:37 Oct 25, 2022
Jkt 259001
Contact Person: Stephanie Christine Nagle
Emmens, Ph.D., Scientific Review Officer,
Center for Scientific Review, National
Institutes of Health, 6701 Rockledge Drive,
Bethesda, MD 20892, (301) 594–6604,
nagleemmenssc@csr.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: October 20, 2022.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2022–23270 Filed 10–25–22; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Amended
Notice of Meeting
Notice is hereby given of a change in
the meeting of the Center for Scientific
Review Special Emphasis Panel RFA
Panel: Tobacco Regulatory Science B,
November 17, 2022, 9:30 a.m.–8:00
p.m., National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
which was published in the Federal
Register on October 20, 2022, 87 FR
63790, Doc 2022–22763.
This notice is being amended to
change the meeting end time from 8:00
p.m. to 8:30 p.m. The meeting is closed
to the public.
Dated: October 20, 2022.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2022–23228 Filed 10–25–22; 8:45 am]
BILLING CODE 4140–01–P
64803
plan to view the virtual meeting and
need special assistance or other
reasonable accommodations to view the
meeting, should notify the Contact
Person listed below in advance of the
meeting. The open session will be
videocast and can be accessed from the
NIH Videocasting and Podcasting
website (https://videocast.nih.gov).
Name of Committee: Advisory Committee
to the Director, National Institutes of Health.
Date: November 3, 2022.
Time: 5:00 p.m. to 6:00 p.m.
Agenda: New Framework for Peer Review
Criteria, Consideration of Proposed
Establishment of ACD Working Groups, and
Other Business of the Committee.
Place: National Institutes of Health,
Building 1, One Center Drive, Bethesda, MD
20892, (Virtual Meeting).
Contact Person: Cyndi Burrus-Shaw, Staff
Assistant, National Institutes of Health,
Office of the Director, One Center Drive,
Building 1, Room 126, Bethesda, MD 20892,
301–496–2433, shawcy@od.nih.gov.
This notice is being published less
than 15 days prior to the meeting due
to scheduling difficulties.
Any interested person may file
written comments with the committee
by forwarding the statement to the
Contact Person listed on this notice. The
statement should include the name,
address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
Information is also available on the
Institute’s/Center’s home page: https://
acd.od.nih.gov, where an agenda will be
posted before the meeting date.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.14, Intramural Research
Training Award; 93.22, Clinical Research
Loan Repayment Program for Individuals
from Disadvantaged Backgrounds; 93.232,
Loan Repayment Program for Research
Generally; 93.39, Academic Research
Enhancement Award; 93.936, NIH Acquired
Immunodeficiency Syndrome Research Loan
Repayment Program; 93.187, Undergraduate
Scholarship Program for Individuals from
Disadvantaged Backgrounds, National
Institutes of Health, HHS)
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Dated: October 20, 2022.
David W. Freeman,
Program Analyst,Office of Federal Advisory
Committee Policy.
National Institutes of Health
[FR Doc. 2022–23229 Filed 10–25–22; 8:45 am]
Office of the Director, National
Institutes of Health; Notice of Meeting
BILLING CODE 4140–01–P
Pursuant to section 10(a) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the Advisory Committee to
the Director, National Institutes of
Health.
The meeting will be held as a virtual
meeting and will be open to the public
as indicated below. Individuals who
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
PO 00000
Frm 00050
Fmt 4703
Sfmt 4703
National Institutes of Health
National Institute on Drug Abuse;
Notice of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
E:\FR\FM\26OCN1.SGM
26OCN1
64804
Federal Register / Vol. 87, No. 206 / Wednesday, October 26, 2022 / Notices
lotter on DSK11XQN23PROD with NOTICES1
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
Developing Regulated Therapeutic and
Diagnostic Solutions for Patients Affected by
Opioid and/or Stimulants use Disorders.
Date: November 30, 2022.
Time: 10:00 a.m. to 5:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Gerald L. McLaughlin,
Ph.D., Scientific Review Officer, Office of
Extramural Policy and Review, National
Institute on Drug Abuse, NIH, 301 North
Stonestreet Avenue, MSC 6021, Bethesda,
MD 20892, (301) 827–5819 ,gm145a@nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; High
Priority HIV and Substance Use Research.
Date: November 30, 2022.
Time: 12:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Trinh T. Tran, Ph.D,.
Scientific Review Officer, Office of
Extramural Policy and Review, Division of
Extramural Research, National Institute on
Drug Abuse, NIH, 301 North Stonestreet
Avenue, MSC 6021, Bethesda, MD 20892,
(301) 827–5843, trinh.tran@nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
Pathogenic Mechanisms influencing Blood
Brain Barrier function in HIV and Substance
Use Disorders.
Date: December 6, 2022.
Time: 1:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Gerald L. McLaughlin,
Ph.D., Scientific Review Officer, Office of
Extramural Policy and Review, National
Institute on Drug Abuse, NIH, 301 North
Stonestreet Avenue, MSC 6021, Bethesda,
MD 20892, (301) 827–5819, gm145a@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.277, Drug Abuse Scientist
VerDate Sep<11>2014
17:37 Oct 25, 2022
Jkt 259001
Development Award for Clinicians, Scientist
Development Awards, and Research Scientist
Awards; 93.278, Drug Abuse National
Research Service Awards for Research
Training; 93.279, Drug Abuse and Addiction
Research Programs, National Institutes of
Health, HHS)
Dated: October 20, 2022.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2022–23271 Filed 10–25–22; 8:45 am]
BILLING CODE 4140–01–P
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; Improved Drug
Susceptibility Testing (DST) for Tuberculosis
(R01 Clinical Trial Not Allowed).
Date: November 30–December 1, 2022.
Time: 9:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Allergy and
Infectious Diseases; National Institutes of
Health, 5601 Fishers Lane, Room 3G13,
Rockville, MD 20892 (Virtual Meeting).
Contact Person: Brenda Lange-Gustafson,
Ph.D., Scientific Review Officer, Scientific
Review Program, Division of Extramural
Activities, National Institute of Allergy and
Infectious Diseases; National Institutes of
Health, 5601 Fishers Lane, Room 3G13,
Rockville, MD 20852, 240–669–5047,
bgustafson@niaid.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Frm 00051
Fmt 4703
[FR Doc. 2022–23272 Filed 10–25–22; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Fiscal Year (FY) 2023 Funding
Opportunity
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
PO 00000
Dated: October 20, 2022.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory
Committee Policy.
Sfmt 4703
Substance Abuse and Mental
Health Services Administration, HHS.
ACTION: Notice of intent to award a
single source cooperative agreement to
the Mental Health Association of New
York City, Inc. (DBA Vibrant Emotional
Health).
AGENCY:
This notice is to inform the
public that the Substance Abuse and
Mental Health Services Administration
(SAMHSA) intends to award $47
million (total costs) for up to one year
to Vibrant Emotional Health for the 988
Suicide and Crisis Lifeline Access
Improvement Project. Funding for this
program is from the Bipartisan Safer
Communities Act, [Pub. L. 117–159,
Division B, Title II]. Under this
cooperative agreement, Vibrant
Emotional Health will expand access to
the local and national Lifeline backup
centers, language services, system
evaluation and data reporting, and
access to specialized care for
populations to be known at higher risk
for suicide by: (1) expanding options for
connection and support for individuals
at higher risk of suicide, which includes
but is not limited to LGBTQI+,
American Indian/Alaska Native, rural
individuals, individuals with mental
illness and substance use disorders,
Black/African-American youth and
older men; (2) expanding current
language access services to include
Spanish chat and text, and videophone
for those deaf and hard of hearing; and
(3) improve access and capacity
utilization of the nationwide backup
system while maximizing state and
territory response.
Funding Opportunity Title: 988
Suicide and Crisis Lifeline Access
Improvement Project.
Assistance Listing Number: 93.243.
Authority: Section 520E–3 of the
Public Health Service Act, as amended.
Justification: Eligibility for this award
is limited to the Mental Health
Association of New York City, Inc. (DBA
Vibrant Emotional Health). Vibrant
Emotional Health is the current Lifeline
SUMMARY:
E:\FR\FM\26OCN1.SGM
26OCN1
]]>Agencies
[Federal Register Volume 87, Number 206 (Wednesday, October 26, 2022)]
[Notices]
[Pages 64803-64804]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-23271]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
[[Page 64804]]
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Developing Regulated Therapeutic and Diagnostic
Solutions for Patients Affected by Opioid and/or Stimulants use
Disorders.
Date: November 30, 2022.
Time: 10:00 a.m. to 5:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, National Institute on Drug
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Gerald L. McLaughlin, Ph.D., Scientific Review
Officer, Office of Extramural Policy and Review, National Institute
on Drug Abuse, NIH, 301 North Stonestreet Avenue, MSC 6021,
Bethesda, MD 20892, (301) 827-5819 ,[email protected].
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; High Priority HIV and Substance Use Research.
Date: November 30, 2022.
Time: 12:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, National Institute on Drug
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Trinh T. Tran, Ph.D,. Scientific Review Officer,
Office of Extramural Policy and Review, Division of Extramural
Research, National Institute on Drug Abuse, NIH, 301 North
Stonestreet Avenue, MSC 6021, Bethesda, MD 20892, (301) 827-5843,
[email protected].
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Pathogenic Mechanisms influencing Blood Brain
Barrier function in HIV and Substance Use Disorders.
Date: December 6, 2022.
Time: 1:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, National Institute on Drug
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Gerald L. McLaughlin, Ph.D., Scientific Review
Officer, Office of Extramural Policy and Review, National Institute
on Drug Abuse, NIH, 301 North Stonestreet Avenue, MSC 6021,
Bethesda, MD 20892, (301) 827-5819, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug
Abuse Scientist Development Award for Clinicians, Scientist
Development Awards, and Research Scientist Awards; 93.278, Drug
Abuse National Research Service Awards for Research Training;
93.279, Drug Abuse and Addiction Research Programs, National
Institutes of Health, HHS)
Dated: October 20, 2022.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2022-23271 Filed 10-25-22; 8:45 am]
BILLING CODE 4140-01-P
